ModifiedUnitedHealthcarePolicy CS165PA.J

Genetic Testing for Neurological Disorders (for Pennsylvania Only)

Policy governing coverage of multi-gene (>=5 genes) targeted genetic panel testing for heritable neurological disorders for members in Pennsylvania; applies to provider ordering and medical necessity determinations for UnitedHealthcare Pennsylvania plans.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neurological Disorders (for Pennsylvania Only)

Policy CodePolicy CS165PA.J

Change TypeCoverage criteria reviseddefinitions and code removals

Effective DateJan 1, 2026

Next Review Date

Key ActionOrder targeted multi-gene panels (five or more genes) only when the patient has qualifying signs/symptoms and tests are ordered by or in consultation with an appropriate specialist.

SourceLink

POLICY UPDATE CHANGES

Revised coverage language to indicate multi-gene targeted panel testing (five or more genes) is proven and medically necessary when specific clinical and ordering criteria are met.

Added list of intended diagnostic targets for testing (congenital or metabolic myopathy, ataxia, peripheral neuropathy, hereditary spastic paraplegia, muscular dystrophy).

Comprehensive panel tests evaluating multiple categories of clinically distinct neurological disorders are unproven and not medically necessary.

Clarified that Whole Exome and Whole Genome Sequencing are addressed in a separate UnitedHealthcare policy for non-oncology conditions.

Added medical records documentation requirements that support medical necessity and may be requested for review.

Updated definitions: added definitions for Ataxia, Comprehensive Panel, Congenital Myopathy, Metabolic Myopathy, and Targeted Panel; removed several prior definitions.

Removed CPT codes 0417U, 81440, 81460, and 81465 from Applicable Codes.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

5+Minimum genes for covered panel

4Procedure codes listed

UnprovenComprehensive multi-category panels

Coverage Criteria for Targeted and Comprehensive Panels

Multi-gene Targeted Panel testing (medically necessary)

Covered when ALL of the following are met:

Eligibility for covered multi-gene targeted panel: (1) The individual to be tested displays signs or symptoms of a heritable neurological disorder and the results are expected to directly impact medical management of that disorder; (2) The test is ordered by or in consultation with a medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist; (3) The test is intended to establish a genetic cause for one of: Congenital or Metabolic Myopathy; Ataxia; Peripheral neuropathy; Hereditary spastic paraplegia; Muscular dystrophy.>= 5 genes

Targeted panels defined as five or more genes per policy

Targeted Panel — Medically Necessary

Covered when ALL of the following are met:

Comprehensive panels for multiple clinically distinct neurological disorder categories: Comprehensive panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are unproven and not medically necessary due to insufficient evidence of efficacy.

See policy statement; Whole Exome and Whole Genome Sequencing are addressed in a separate policy.

Multi-gene Targeted Panel — Medically Necessary

Covered when ALL of the following are met:

Targeted panel coverage criteria: (1) Multi-gene targeted panel testing (five or more genes) is ordered; (2) The individual displays signs or symptoms of a heritable neurological disorder and results are expected to directly impact medical management; (3) The test is ordered by or in consultation with a medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist; (4) The test is intended to establish a genetic cause for one of: Congenital or Metabolic Myopathy; Ataxia; Peripheral neuropathy; Hereditary spastic paraplegia; Muscular dystrophy.>= 5 genes

From policy coverage rationale and summary of changes

Comprehensive Panel testing

Comprehensive panel handling: Comprehensive Panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are considered unproven and not medically necessary; Whole Exome and Whole Genome Sequencing are addressed in a separate UnitedHealthcare policy.

See policy 'Coverage Rationale' and 'Clinical Evidence' sections

Comprehensive Panels — Not Medically Necessary

Comprehensive panels: Comprehensive panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are unproven and not medically necessary due to insufficient evidence of efficacy.

These are explicitly considered not medically necessary; WES/WGS handled separately

Comprehensive panel tests that are designed to evaluate genes across multiple, clinically distinct neurological disorder categories are considered not medically necessary. The policy states that such comprehensive multi-category panels are unproven and not medically necessary due to insufficient evidence of efficacy, and coverage for those tests may be denied when submitted for adjudication.

Current evidence does not support the clinical utility of comprehensive panels that evaluate genes unrelated to an individual's phenotype. Studies show genotype–phenotype correlations support targeted, phenotype-driven testing; in contrast, comprehensive panels assess genes that are not linked to the presenting phenotype and therefore lack supporting clinical evidence for routine use.

Whole Exome Sequencing and Whole Genome Sequencing are not adjudicated in this policy. Coverage considerations for WES/WGS are addressed in a separate UnitedHealthcare medical policy titled Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions) (for Pennsylvania Only).

Indications Covered by Targeted Multi-gene Panels

inv-38: Diagnostic evaluation of a symptomatic individual to establish genetic cause for Congenital or Metabolic Myopathy, Ataxia, Peripheral neuropathy, Hereditary spastic paraplegia, or Muscular dystrophy

Panel must be targeted (>=5 genes) and ordered by or in consultation with a specified specialist; results must be expected to directly impact medical management.

Diagnostic evaluation for listed disorders: The diagnostic evaluation of a symptomatic individual to establish a genetic cause for any one of the following is covered when a targeted multi-gene panel (five or more genes) is used and ordering and clinical criteria are met: Congenital or Metabolic Myopathy; Ataxia; Peripheral neuropathy; Hereditary spastic paraplegia; Muscular dystrophy.>= 5 genes

Test must be ordered by or in consultation with a medical geneticist, developmental pediatrician, or adult/pediatric neuromuscular or neurogenetics specialist

inv-40: To establish a genetic cause for listed diagnostic categories when targeted multi-gene panels (>=5 genes) meet clinical and ordering criteria

Coverage when targeted panels meet criteria:

Applicable Procedure and CPT Codes

Applicable procedure codes referencedCPT

0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.
0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.
81448	Hereditary peripheral neuropathies (e.g., Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (e.g., BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1).
81479	Unlisted molecular pathology procedure

Removed CPT CodesCPT

0417U	Removed from Applicable Codes
81440	Removed from Applicable Codes
81460	Removed from Applicable Codes
81465	Removed from Applicable Codes

Previously listed CPT codes removedCPT

0417U	Removed
81440	Removed
81460	Removed
81465	Removed

Panel gene count threshold — policy threshold

Policy panel gene count threshold>= 5 genes

ContextTargeted multi-gene panels testing five or more genes are defined as the threshold for coverage when clinical and ordering criteria are met.

Related codes noteCertain CPT-listed panels require at least 5 genes (see Applicable Codes, e.g., 81448).

Panel size threshold — policy threshold

Panel size threshold>= 5 genes

Policy changeOperationalized in 01/01/2026 revision: targeted panels of five or more genes specified for coverage.

Ordering, Documentation, and Prior Authorization Requirements

Prior Authorization

Prior Authorization Required / Ordering Requirements

Multi-gene targeted panel testing (five or more genes) must meet the policy's medical necessity criteria and may require prior authorization. Orders should be placed appropriately and by an approved specialist as detailed below.

Prior authorization may be required for multi-gene panel testing (targeted panels ≥5 genes).
Ordering provider requirement: test must be ordered by or in consultation with a medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist.
Tests ordered by non-specified providers may be denied if specialist involvement is not documented.
Comprehensive multi-category panels (panels that evaluate multiple clinically distinct neurological disorder categories) are considered not medically necessary and may be denied.
Medical records documentation must fully support medical necessity (see documentation details below).

Member and Test Eligibility

No additional top‑level eligibility requirements were extracted for this section.

Tests and Services Not Covered

Comprehensive panels intended to evaluate genes across multiple categories of clinically distinct neurological disorders are explicitly listed as not covered / not medically necessary. The policy indicates such multi‑category panels are unproven because evidence does not demonstrate clinical utility for assessing genes unrelated to the member’s phenotype. Note that Whole Exome and Whole Genome Sequencing considerations are handled under a separate policy.

The policy explicitly states that comprehensive multi‑category panels are unproven and not medically necessary. This stance reflects the lack of supportive clinical evidence for panels that include genes across unrelated neurological disorder categories and the preference for phenotype‑directed targeted testing.

Comprehensive panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are considered not medically necessary. Clinical evidence summarized in the policy indicates that phenotype‑guided testing (targeted panels) is more appropriate because comprehensive panels include genes not relevant to the presenting phenotype and lack demonstrated clinical utility.

Definitions and Terminology

Targeted Panel — definition

Targeted Panel (general)A curated assay that simultaneously tests more than one gene associated with a condition; may include multiple genes for one condition or genes associated with a symptom or non-specific presentation.

Targeted Panel (policy-specific)A multi-gene panel testing five or more genes tailored to a specific clinical phenotype or disorder category (used for coverage determinations).

Clinical useIntended to establish a genetic cause for a specific disorder category (e.g., congenital myopathy, ataxia, peripheral neuropathy).

Comprehensive Panel — definition

Comprehensive Panel (general)An assay that simultaneously tests more than one gene associated with a variety of conditions, symptoms, or non-overlapping clinical presentations.

Policy stance

Background and Clinical Context

Heritable neurological disorders encompass a broad range of neuromuscular, neurodegenerative, and peripheral nerve conditions. Genetic testing options range from focused, phenotype‑driven multi‑gene panels to broader assays such as whole exome or whole genome sequencing. The policy emphasizes that phenotype‑directed multi‑gene targeted panels (five or more genes) are the proven approach when specific clinical signs or symptoms align with known gene–disease associations, whereas broader comprehensive panels lack sufficient evidence of clinical utility and are not covered under this policy.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neurological Disorders (for Pennsylvania Only)

Policy CodePolicy CS165PA.J

Change TypeCoverage criteria reviseddefinitions and code removals

Effective DateJan 1, 2026

Next Review Date

Key ActionOrder targeted multi-gene panels (five or more genes) only when the patient has qualifying signs/symptoms and tests are ordered by or in consultation with an appropriate specialist.

SourceLink

On This Page

Coverage to establish a genetic cause for the listed diagnostic categories applies when a targeted multi-gene panel (five or more genes) is ordered, the individual displays relevant signs or symptoms with results expected to impact management, and the test is ordered by or in consultation with an appropriate specialist.

Targeted panels defined as five or more genes; comprehensive panels are not covered

inv-39: Estabishing a genetic cause for the listed diagnostic categories (placeholder for exact leaf criteria)

Establishing a genetic cause — required elements: The test must be intended to establish a genetic cause for one of: Congenital or Metabolic Myopathy; Ataxia; Peripheral neuropathy; Hereditary spastic paraplegia; Muscular dystrophy, and documentation must show that results are expected to directly impact medical management. The panel must be a targeted multi-gene panel of five or more genes and ordered by or in consultation with the specified specialists.>= 5 genes

Medical records documenting history, exam, and pertinent diagnostic tests may be requested to support medical necessity

Coverage implicationPanels meeting this size and clinical criteria may be considered medically necessary; larger comprehensive multi-category panels are unproven.

Minimum genes for targeted panel — policy threshold

Minimum genes for a targeted panelFive or more genes

Definition linkageTargeted panels testing five or more genes are tailored to a specific clinical phenotype or disorder category for coverage determination.

Ordering requirementCoverage requires that a targeted panel (≥5 genes) be ordered by or in consultation with an appropriate specialist.

Documentation Required

Medical Records Documentation Required

The patient's medical record must contain documentation that fully supports medical necessity for the requested genetic test. This documentation should be legible, maintained in the patient's medical record, and made available upon request. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage.

Required content includes, but is not limited to: relevant medical history, physical examination findings, and results of pertinent diagnostic tests or procedures that support the diagnosis and the need for the specific genetic test.
Documentation must demonstrate that the individual displays signs or symptoms of a heritable neurological disorder and that test results are expected to directly impact medical management.
If the test was ordered after consultation, include documentation of the specialist consultation (name, specialty, and clinical rationale).

Denial Risk

Denial Risk / Documentation and Ordering Provider

Requests may be denied if clinical criteria are not met or the medical record lacks sufficient documentation to support the requested testing. Tests ordered by providers who are not among the specified specialists may be denied unless appropriate specialist consultation is documented. Comprehensive multi-category panels are not medically necessary and will be denied.

Denial risk if documentation does not show signs/symptoms of a heritable neurological disorder or expected impact on management.
Denial risk if ordering provider is not a medical geneticist, developmental pediatrician, or neuromuscular/neurogenetics specialist and no consultation is documented.
Denial risk for comprehensive panels that span multiple distinct neurological disorder categories due to insufficient evidence of efficacy.

Note

Clinical Intent and Indication

For proven medically necessary targeted panels, ensure the test's clinical intent is documented (for example: to establish a genetic cause for congenital or metabolic myopathy, ataxia, peripheral neuropathy, hereditary spastic paraplegia, or muscular dystrophy).

Clearly state the suspected diagnosis or diagnostic category linked to the requested panel.
Document how the genetic test result will influence patient management, surveillance, or treatment.

Comprehensive Panel: panels intended to evaluate multiple genes across multiple clinically distinct neurological disorder categories are considered unproven and not medically necessary.

Coverage noteWES/WGS considerations are addressed in a separate policy and are not adjudicated here.

Targeted Panel — updated definition

Updated Targeted Panel definitionTargeted Panel: a multi-gene panel testing five or more genes tailored to a specific clinical phenotype or disorder category.

Effective changeOperationalized in the 01/01/2026 policy revision to specify ≥5 genes for targeted panels used in neurological disorder evaluations.

Coverage linkageTargeted panels meeting this definition are considered medically necessary when clinical and ordering criteria are satisfied.

Comprehensive Panel — updated definition

Updated Comprehensive Panel descriptionComprehensive Panel: a panel intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders.

Policy implicationSuch comprehensive multi-category panels are unproven and not medically necessary due to insufficient evidence.

Related guidanceWhole Exome and Whole Genome Sequencing are addressed separately and not adjudicated here.

Ataxia — definition added

Ataxia — defined diagnostic categoryAtaxia: a condition of the nervous system that causes loss of control of muscle movement and coordination; may be a symptom or a standalone condition.

Coverage relevanceAtaxia is explicitly listed as one of the intended diagnostic targets for targeted panel testing coverage.

Context in definitionsAdded to policy definitions in the 01/01/2026 revision alongside other disorder-specific definitions.

Definitions added — list of new definitions

Definitions addedAdded definitions for Ataxia, Comprehensive Panel, Congenital Myopathy, Metabolic Myopathy, and Targeted Panel in the policy.

Removed definitionsPrior definitions removed include Comparative Genomic Hybridization (CGH), Neuromuscular Disorders (NMD), Next Generation Sequencing (NGS), and Variant of Unknown Significance (VUS).

Effective date noteThese terminology changes and additions are part of the 01/01/2026 policy revision.